PierianDx Announces Clinical Microarray Technology Will Be Integrated into Its End-to-End Genomics Platform for Clinical Labs
22 September 2017 - 5:19AM
Business Wire
PierianDx, the forerunner in clinical genomic analysis,
interpretation and reporting, announced that its leading,
integrated “one space” genomics workflow and analysis solution,
Clinical Genomicist Workspace (CGW), now supports clinical
microarray (CMA) technology.
CMA is commonly used in the constitutional setting to evaluate
complex developmental disorders and is used to identify potential
copy number variations (CNVs) that explain one or more relevant
clinical phenotypes observed in the patient. While in recent years
Next Generation Sequencing (NGS) has become the gold-standard for
clinical genomics because of its more comprehensive analysis and
increasingly lower price point, CMA is still widely used in the
industry.
Integrating CMA into CGW is a part of PierianDx’s continued goal
to be the “one space” clinical labs turn to for an integrated
molecular diagnostics workflow, analysis and interpretation
platform, said PierianDx CEO Ted Briscoe.
“We have always been committed to offering a comprehensive
molecular diagnostic solution that is assay and technology agnostic
and easily integrated into our customers’ enterprise ecosystems,”
said Briscoe.
Some of the CMA enhancements within CGW include:
- Workflow integration to submit
processed microarray results from a batch of samples to generation
of a templated report without user intervention
- Ability to review, sort and filter copy
number variants (CNV) as well as loss of heterozygosity (LOH)
segments and associated quality information
- Ability to set laboratory-specific
validation filters for CNV and LOH segments as well as specific
panel- and case-specific filters
- Clinical interpretations that are
automatically inferred in patient cases for review and editing
- An updated knowledgebase that includes
published literature for articles that mention cytogenetic
positions, genes, and phenotypes associated with a patient
case
CMA enhancements will be featured in PierianDx’s upcoming CGW
webinar on Thursday, Sept. 28, 2017 at 11 am CDT. To register for
the webinar, visit http://pieriandx.com/events.
About PierianDx
PierianDx enables clinical labs to deliver patient-specific
diagnosis and treatments based on an individual’s DNA for cancers
and hereditary diseases. Utilizing PierianDx’s comprehensive and
integrated “one space” NGS workflow and analysis solution, Clinical
Genomicist Workspace (CGW), clinical labs create more streamlined
and accurate analysis, interpretation, and reporting needed to
accelerate their personalized medicine programs. For more
information, please visit www.pieriandx.com or @PierianDx on
Twitter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170921006107/en/
PierianDxBrad Herrick,
314-238-4476brad.herrick@pieriandx.com